{"id":"tiotropium-formoterol","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nervousness/anxiety"},{"rate":null,"effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL1256786","moleculeType":"Small molecule","molecularWeight":"344.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium acts as a muscarinic M3 receptor antagonist, preventing acetylcholine-induced bronchoconstriction and reducing mucus secretion. Formoterol activates beta-2 adrenergic receptors on airway smooth muscle, increasing cAMP and causing sustained bronchodilation. The combination provides complementary mechanisms for maintenance therapy in COPD and asthma.","oneSentence":"Tiotropium is a long-acting anticholinergic that blocks muscarinic receptors to relax airway smooth muscle, while formoterol is a long-acting beta-2 agonist that stimulates bronchodilation, together providing sustained airway opening for chronic obstructive pulmonary disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:52.747Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"},{"name":"Asthma maintenance therapy"}]},"trialDetails":[{"nctId":"NCT06282861","phase":"PHASE4","title":"ANTES B+ Clinical Trial","status":"TERMINATED","sponsor":"Fundacio Privada Mon Clinic Barcelona","startDate":"2024-02-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03083067","phase":"NA","title":"Salvational Intervention for Reducing AECOPD Under Severe Air Pollution","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2017-03-20","conditions":"COPD Exacerbation, Air Pollution","enrollment":402},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT01911364","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3686},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT02676089","phase":"PHASE3","title":"TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04-06","conditions":"Asthma","enrollment":1433},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT04520230","phase":"PHASE4","title":"Three Treatment of Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2014-10-31","conditions":"COPD","enrollment":45},{"nctId":"NCT02988869","phase":"PHASE4","title":"Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2016-08","conditions":"COPD","enrollment":84},{"nctId":"NCT03275116","phase":"PHASE4","title":"The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2017-07-07","conditions":"Chronic Obstructive Airway Disease","enrollment":49},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT04137029","phase":"NA","title":"Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, Pulmonology Scientific Research Institute","startDate":"2019-04-24","conditions":"Health, Subjective, Hyperreactivity, Bronchial","enrollment":20},{"nctId":"NCT01794780","phase":"PHASE4","title":"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-05","conditions":"COPD","enrollment":2229},{"nctId":"NCT00773786","phase":"PHASE4","title":"Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Trinity Health Of New England","startDate":"2008-10","conditions":"COPD","enrollment":20},{"nctId":"NCT02546297","phase":"PHASE4","title":"Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2017-09-15","conditions":"COPD, Bronchiectasis","enrollment":90},{"nctId":"NCT01656005","phase":"PHASE4","title":"Beta Blocker Therapy in Moderate to Severe COPD","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2012-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":18},{"nctId":"NCT00996697","phase":"PHASE4","title":"Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2006-10","conditions":"COPD","enrollment":23},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02275481","phase":"PHASE4","title":"A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":66},{"nctId":"NCT03504527","phase":"NA","title":"Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-05-01","conditions":"Asthma-COPD Overlap","enrollment":120},{"nctId":"NCT01290874","phase":"PHASE3","title":"Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-03-30","conditions":"Asthma","enrollment":1070},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT03258749","phase":"NA","title":"Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2017-11-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":120},{"nctId":"NCT01332461","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":5677},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT01085045","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":118},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT02347072","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":80},{"nctId":"NCT01854645","phase":"PHASE3","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2103},{"nctId":"NCT00139932","phase":"PHASE4","title":"Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT01587079","phase":"PHASE2","title":"Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":159},{"nctId":"NCT00546234","phase":"PHASE4","title":"Tiotropium for Smoking Asthmatics Study","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2007-11","conditions":"Asthma","enrollment":""},{"nctId":"NCT01917643","phase":"","title":"Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"COPD Exacerbation","enrollment":2396},{"nctId":"NCT02257463","phase":"NA","title":"Effect of Inspiratory Muscle Training on Exercise Performance and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":60},{"nctId":"NCT01397890","phase":"PHASE4","title":"Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":793},{"nctId":"NCT02242240","phase":"PHASE2","title":"Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":95},{"nctId":"NCT02238119","phase":"PHASE2","title":"Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":74},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT00239421","phase":"PHASE4","title":"A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":605},{"nctId":"NCT01466712","phase":"PHASE4","title":"Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function","status":"UNKNOWN","sponsor":"KU Leuven","startDate":"2011-11","conditions":"COPD, Emphysema, Small Airway Disease","enrollment":20},{"nctId":"NCT00496470","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":660},{"nctId":"NCT00424528","phase":"PHASE4","title":"Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema","enrollment":235},{"nctId":"NCT00134979","phase":"PHASE4","title":"Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":847},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059},{"nctId":"NCT00507234","phase":"PHASE3","title":"Study in Subjects Greater Than 40 Years of Age With COPD","status":"COMPLETED","sponsor":"Dey","startDate":"2007-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":128},{"nctId":"NCT00680056","phase":"PHASE4","title":"Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2007-11","conditions":"Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis, Pulmonary Emphysema","enrollment":33},{"nctId":"NCT00668408","phase":"PHASE4","title":"LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2008-05","conditions":"Lung Diseases, Obstructive, Chronic Heart Failure, Chronic Hypoxemia","enrollment":1000},{"nctId":"NCT00308191","phase":"PHASE3","title":"A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD","status":"COMPLETED","sponsor":"Dey","startDate":"2006-04","conditions":"COPD","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TRITON 18/12 mcg Discair Inhalation Powder"],"phase":"marketed","status":"active","brandName":"Tiotropium/Formoterol","genericName":"Tiotropium/Formoterol","companyName":"Neutec Ar-Ge San ve Tic A.Ş","companyId":"neutec-ar-ge-san-ve-tic-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tiotropium/Formoterol is a small molecule medication used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and COPD exacerbation. It is a combination of tiotropium, an anticholinergic, and formoterol, a long-acting beta2-adrenergic receptor agonist (LABA), which work together to improve lung function and alleviate symptoms.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}